Krystal Biotech (KRYS) PT Raised to $103 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the price target on Krystal Biotech (NASDAQ: KRYS) to $103.00 (from $84.00) while maintaining a Buy rating.

The analyst commented, "This morning, Krystal announced 4Q20 and full year results, posting EPS of ($0.53) and ($1.71) compared to our estimate of ($0.50) and ($1.68) and consensus of ($0.61) and ($1.79). The company ended the year financially strong with $271.3 million in cash, excluding the net proceeds from a recently completed public offering of $151 million. Current funding should support all ongoing clinical programs, the pipeline expansion to pulmonary indications, and the company’s manufacturing initiatives to support the growing pipeline demand. Key operational updates are projecting important milestones upcoming in the next six to 12 months. We see multiple value-creating opportunities in 2021, adding confidence to our thesis."

You May Also Be Interested In

• Gartner (IT) PT Lowered to $206 at BMO Capital, adjusting estimates
• Duos Technologies Group (DUOT) PT Raised to $27 at Cantor Fitzgerald on 'Extremely Attractive' Risk/Reward
• Motorcar Parts of America (MPAA) PT Lowered to $16 at Freedom Broker